Oppenheimer analyst Hartaj Singh lowered the price target on Spruce Biosciences, Inc. (NASDAQ: SPRB) to $4.00 (from $7.00) while maintaining ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst PT Change

H.C. Wainwright Downgrades Spruce Biosciences, Inc. (SPRB) to NeutralMarch 14, 2024 8:07 AM Guggenheim Downgrades Spruce Biosciences, Inc. (SPRB) to NeutralMarch 14, 2024 7:13 AM Ladenburg Thalmann Downgrades Spruce Biosciences, Inc. (SPRB) to Neutral, 'Regulatory Path Unclear'March 14, 2024 6:49 AM Leerink Partners Downgrades Spruce Biosciences, Inc. (SPRB) to Market PerformMarch 14, 2024 6:19 AM Spruce Biosciences, Inc. (SPRB) PT Lowered to $3 at JMP Securities, 'We wanted to see a clean safety profile'March 14, 2024 2:40 AM RBC Capital Downgrades Spruce Biosciences, Inc. (SPRB) to Sector Perform, 'Trial Miss Puts Tilda’ Future in Flux'March 13, 2024 9:50 PM After-hours movers: UiPath, SentinelOne, Under Armour, and moreMarch 13, 2024 4:42 PM Form 8-K SPRUCE BIOSCIENCES, INC. For: Mar 10March 13, 2024 4:13 PM Spruce Biosciences Reports Full Year 2023 Financial Results and Provides Corporate UpdatesMarch 13, 2024 4:08 PM Spruce Biosciences (SPRB) Halted, News PendingMarch 13, 2024 4:02 PM Spruce Biosciences (SPRB) Announces Topline Results from CAHmelia-203March 13, 2024 4:01 PM